clinical trial · NCT07896941
Safety and Efficacy of CG-BM1 in Ischemic Stroke
GuangZhou Cellgenes Biotechnology Co., Ltd.·phase2·recruiting·n = 87
Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)single infusion, 1.0 × 10^6 cells/kgsingle infusion, 2.0 × 10^6 cells/kgsingle infusion, 3.0 × 10^6 cells/kg1.0 × 10^6 cells/kg once every two weeks for a total of 3 doses2.0 × 10^6 cells/kg once every two weeks for a total of 3 doses3.0 × 10^6 cells/kg once every two weeks for a total of 3 dosesPlacebo, once every two weeks for a total of 3 doses.
brief summary
1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke. 2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients.
started
Sep 30, 2024
primary completion
Dec 30, 2028
completion
Dec 30, 2029
last updated
Oct 28, 2026
official title
A Clinical Trial to Evaluate the Safety and Efficacy of Allogeneic Human Bone Marrow Mesenchymal Stem Cell (CG-BM1) Injection in the Treatment of Ischemic Stroke
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol